Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.79 |
| ▸ | DRD2 | P14416 | 4/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.67 |
| ▸ | DRD3 | P35462 | 3/20 | 0.63 |
| ▸ | HTR1A | P08908 | 3/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594226 | 0.95 | KCNH2 (0.79) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL27695348 | 0.93 | KCNH2 (0.83) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL15920946 | 0.93 | KCNH2 (0.83) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL7126924 | 0.90 | SIGMAR1 (0.65) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL27822324 | 0.89 | SIGMAR1 (0.64) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL3453669 | 0.89 | DRD2 (1.00) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL15690402 | 0.89 | KCNH2 (0.70) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL5988317 | 0.88 | KCNH2 (0.88) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 | |
| SCHEMBL4528457 | 0.86 | KCNH2 (1.00) | SIGMAR1DRD2KCNH2CYP2D6DRD3 | |
| SCHEMBL9041083 | 0.84 | KCNH2 (0.80) | SIGMAR1DRD2KCNH2CYP2D6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021046438-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-11 | — | — | WO | disclosed |
| CN-107226796-B | A kind of method that visible light catalytic piperazine compounds are selectively cyanalation | 陕西师范大学 | 2019-08-20 | — | — | CN | disclosed |
| EP-2791142-B1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | US HEALTH (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018140630-A1 | AUTOPHAGY INDUCERS FOR TREATMENT OF CNS CONDITIONS | NORTHWESTERN UNIVERSITY (US) | 2018-08-02 | — | — | WO | disclosed |
| CN-107226796-A | A kind of visible light catalytic piperazine compounds selectively cyanalation method | 陕西师范大学 | 2017-10-03 | — | — | CN | disclosed |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663521-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | NORTHWESTERN UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| WO-2013090912-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-06-20 | — | — | WO | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM SPA, ITALY | 2007-08-23 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-6991902-B2 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6893815-B1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| EP-1075469-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000052001-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999000669-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | SIGMAR1 2349/4885DRD2 3948/4885KCNH2 4364/4885 |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | SIGMAR1 2349/4885DRD2 3948/4885KCNH2 4364/4885 |
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | PNP, ATIC, DPYD | SIGMAR1 2307/4885DRD2 835/4885KCNH2 3340/4885 |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | PNP, ATIC, DPYD | SIGMAR1 2307/4885DRD2 835/4885KCNH2 3340/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | SIGMAR1 2364/4885DRD2 947/4885KCNH2 3445/4885 |
| US-20070197546-A1 | QUINOLINE-4-CARBOXAMIDE AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | KCNH2, KCNH3, KCNJ2 | SIGMAR1 350/4885DRD2 176/4885KCNH2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.